Review article : Associations between immune activation, intestinal permeability and the irritable bowel syndrome
© 2012 Blackwell Publishing Ltd..
BACKGROUND: Irritable bowel syndrome (IBS), one of the most common gastrointestinal disorders, markedly impairing patients' quality of life. Drug development for IBS treatment has been hampered by the lack of understanding of IBS aetiology. In recent years, numerous data have emerged that suggest the involvement of immune activation in IBS, at least in a subset of patients.
AIM: To determine whether immune activation and intestinal permeabilisation are more frequently observed in IBS patients compared with healthy controls.
METHODS: The scientific bibliography was searched using the following keywords: irritable bowel syndrome, inflammation, immune activation, permeabilisation, intestine, assay, histology and human. The retrieved studies, including blood, faecal and histological studies, were analysed to provide a comprehensive and structured overview of the available data including the type of assay, type of inflammatory marker investigated or intestinal segment studied.
RESULTS: Immune activation was more frequently observed in IBS patients than in healthy controls. An increase in the number of mast cells and lymphocytes, an alteration in cytokine levels and intestinal permeabilisation were reported in IBS patients. No consistent changes in the numbers of B cells or enterochromaffin cells or in mucosal serotonin production were demonstrated.
CONCLUSIONS: The changes observed were modest and often heterogeneous among the studied population. Only appropriate interventions improving irritable bowel syndrome symptoms could highlight and confirm the role of immune activation in this pathophysiology.
| Errataetall: |
CommentIn: Aliment Pharmacol Ther. 2013 Jan;37(2):277-8. - PMID 23252779 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2012 |
|---|---|
| Erschienen: |
2012 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 36(2012), 11-12 vom: 31. Dez., Seite 1009-31 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matricon, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 09.04.2013 Date Revised 08.04.2022 published: Print-Electronic CommentIn: Aliment Pharmacol Ther. 2013 Jan;37(2):277-8. - PMID 23252779 Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.12080 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM221835113 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM221835113 | ||
| 003 | DE-627 | ||
| 005 | 20231224052826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.12080 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0739.xml |
| 035 | |a (DE-627)NLM221835113 | ||
| 035 | |a (NLM)23066886 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matricon, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Review article |b Associations between immune activation, intestinal permeability and the irritable bowel syndrome |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2013 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Aliment Pharmacol Ther. 2013 Jan;37(2):277-8. - PMID 23252779 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2012 Blackwell Publishing Ltd. | ||
| 520 | |a BACKGROUND: Irritable bowel syndrome (IBS), one of the most common gastrointestinal disorders, markedly impairing patients' quality of life. Drug development for IBS treatment has been hampered by the lack of understanding of IBS aetiology. In recent years, numerous data have emerged that suggest the involvement of immune activation in IBS, at least in a subset of patients | ||
| 520 | |a AIM: To determine whether immune activation and intestinal permeabilisation are more frequently observed in IBS patients compared with healthy controls | ||
| 520 | |a METHODS: The scientific bibliography was searched using the following keywords: irritable bowel syndrome, inflammation, immune activation, permeabilisation, intestine, assay, histology and human. The retrieved studies, including blood, faecal and histological studies, were analysed to provide a comprehensive and structured overview of the available data including the type of assay, type of inflammatory marker investigated or intestinal segment studied | ||
| 520 | |a RESULTS: Immune activation was more frequently observed in IBS patients than in healthy controls. An increase in the number of mast cells and lymphocytes, an alteration in cytokine levels and intestinal permeabilisation were reported in IBS patients. No consistent changes in the numbers of B cells or enterochromaffin cells or in mucosal serotonin production were demonstrated | ||
| 520 | |a CONCLUSIONS: The changes observed were modest and often heterogeneous among the studied population. Only appropriate interventions improving irritable bowel syndrome symptoms could highlight and confirm the role of immune activation in this pathophysiology | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Meleine, M |e verfasserin |4 aut | |
| 700 | 1 | |a Gelot, A |e verfasserin |4 aut | |
| 700 | 1 | |a Piche, T |e verfasserin |4 aut | |
| 700 | 1 | |a Dapoigny, M |e verfasserin |4 aut | |
| 700 | 1 | |a Muller, E |e verfasserin |4 aut | |
| 700 | 1 | |a Ardid, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 36(2012), 11-12 vom: 31. Dez., Seite 1009-31 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2012 |g number:11-12 |g day:31 |g month:12 |g pages:1009-31 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.12080 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2012 |e 11-12 |b 31 |c 12 |h 1009-31 | ||